Califf's Priorities Feature Short- And Long-Term Goals Despite Potentially Brief Tenure
This article was originally published in The Tan Sheet
Executive Summary
Newly confirmed FDA Commissioner Robert Califf should not assume he will be leaving once a new president arrives, a Republican-appointed predecessor says. Industry trade groups ask Califf to make supplement industry regulation an early priority.
You may also be interested in...
Drug Pricing Activity At US FDA May Be Unique To Gottlieb Tenure
Steven Grossman argues that the former commissioner possessed the credentials to be out front on the pricing issue, unlike other recent FDA commissioners and the current holder of the office.
Gottlieb Advances, But FDA's Future Seems Increasingly Partisan
Senate committee votes to send the FDA Commissioner nominee to the Senate floor, but with only two Democratic votes.
FDA's Commissioner Fish Story Continues
US FDA met with a group concerned about seafood consumption advice for pregnant and nursing women; could it satisfy Sen. Murkowski and avoid a hold on Scott Gottlieb's nomination?